

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50164/026005 10/777,517 Jost-Price et al. February 12, 2004 1612 September 22, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 C.F.R. § 1.98(b))	

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
/B.P./	Ahmed et al., "Treatment of Refractory Temporal Arteritis with Adalimumab," <i>Clin. Rheumatol.</i> 26:1353-1355, 2007.		
/B.P./	Ardizzone et al., "Inflammatory Bowel Disease: New Insights Into Pathogenesis and Treatment," <i>J. Intern. Med.</i> 252:475-496, 2002.		
/B.P./	Badger et al., "Disease-Modifying Activity of SB 242235, A Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, in Rat Adjuvant-Induced Arthritis," <i>Arth. Rheum.</i> 43:175-183, 2000.		
/B.P./	Beck et al., "Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations?" <i>Acta. Neurol. Scand.</i> 78:318-323, 1998.		
/B.P./	Braun et al., "Anti-Tumour Necrosis Factor $\alpha$ Therapy for Ankylosing Spondylitis: International Experience," <i>Ann. Rheum. Dis.</i> 61:iii51-iii60, 2002.		
/B.P./	Braun et al., "Therapy of Ankylosing Spondylitis and Other Spondyloarthritides: Established Medical Treatment, Anti-TNF- $\alpha$ Therapy and Other Novel Approaches," <i>Arth. Res.</i> 4:307-321, 2002.		
/B.P./	Cantini et al., "Treatment of Longstanding Active Giant Cell Arteritis with Infliximab: Report of Four Cases," <i>Arth. Rheum.</i> 44:2933-2935, 2001.		
/B.P./	Crew et al., "Transgenic Mice Expressing a Truncated <i>Peromyscus leucopus</i> TNF- $\alpha$ Gene Manifest an Arthritis Resembling Ankylosing Spondylitis," <i>J. Interferon Cytokine Res.</i> 18:219-225, 1998.		
/B.P./	Durie et al., "Collagen-Induced Arthritis as a Model of Rheumatoid Arthritis," <i>Clin. Immunol. Immunopathol.</i> 73:11-18, 1994.		
EXAMINER	/Benjamin Packard/	DATE CONSIDERED	12/31/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50164/026005 10/777,517 Jost-Price et al. February 12, 2004 1612 September 22, 2008
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/B.P./	Edwards, "PEGylated Recombinant Human Soluble Tumour Necrosis Factor Receptor Type 1 (r-Hu-sTNF-RI): Novel High Affinity TNF Receptor Designed for Chronic Inflammatory Diseases," <i>Ann. Rheum. Dis.</i> 58:173-181, 1999.
/B.P./	Elenkov et al., "Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity," <i>Ann. N. Y. Acad. Sci.</i> 966:290-303, 2002.
/B.P./	Ettehadi et al., "Elevated Tumour Necrosis Factor-Alpha (TNF- $\alpha$ ) Biological Activity in Psoriatic Skin Lesions," <i>Clin. Exp. Immunol.</i> 96:146-151, 1994.
/B.P./	Feldmann et al., "Anti-TNF $\alpha$ Therapy of Rheumatoid Arthritis: What Have We Learned?" <i>Annu. Rev. Immunol.</i> 19:163-196, 2001.
/B.P./	Field et al., "Immuno-Localisation of Tumour Necrosis Factor and Its Receptors in Temporal Arteritis," <i>Rheumatol. Int.</i> 17:113-118, 1997.
/B.P./	Ganesan et al., "Therapeutic Inhibitors of Tumor Necrosis Factor in Crohn's Disease," <i>Curr. Opin. Invest. Drugs</i> 3:1301-1306, 2002.
/B.P./	Gorman et al., "Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor $\alpha$ ," <i>N. Eng. J. Med.</i> 346:1349-1356, 2002.
/B.P./	Khoury et al., "Changes in Serum Levels of ICAM and TNF-R Correlate with Disease Activity in Multiple Sclerosis," <i>Neurology</i> 53:758, 1999.
/B.P./	Krueger et al., "Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis," <i>Arch. Dermatol.</i> 140:218-225, 2004.
/B.P./	Lichtenstein, "Is Infliximab Effective for Induction of Remission in Patients with Ulcerative Colitis?" <i>Inflammatory Bowel Diseases</i> 7:89-93, 2001.
/B.P./	Mashkovsky, "Interactions Between Medicaments," <i>Novaya Volna</i> 1:11, 2001.
/B.P./	Mashkovsky, "Interactions Between Medicaments," <i>Novaya Volna</i> 1:11, 2001. (English translation)
/B.P./	Mashkovsky, "Adrenal Cortical Hormones and Synthetic Analogues Thereof," <i>Novaya Volna</i> 2:25, 2001.
/B.P./	Mashkovsky, "Adrenal Cortical Hormones and Synthetic Analogues Thereof," <i>Novaya Volna</i> 2:25, 2001. (English translation)
/B.P./	Martinez-Taboada et al., "A Double-Blind Placebo Controlled Trial of Etanercept in Patients with Giant Cell Arteritis and Corticosteroid Side Effects," <i>Ann. Rheum. Dis.</i> 67:625-630, 2008.
/B.P./	Mattey et al., "Association of Giant Cell Arteritis and Polymyalgia Rheumatica with Different Tumor Necrosis Factor Microsatellite Polymorphisms," <i>Arth. Rheum.</i> 43:1749-1755, 2000.

EXAMINER	/Benjamin Packard/	DATE CONSIDERED	12/31/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50164/026005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/777,517
		Applicant Jost-Price et al.
		Filing Date February 12, 2004
		Group 1612
(37 C.F.R. § 1.98(b))		IDS Filed September 22, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/B.P./	Migliore et al., "TNF-alpha Blockade Induce Clinical Remission in Patients Affected by Polymyalgia Rheumatica Associated to Diabetes Mellitus and/or Osteoporosis: a Seven Cases Report," <i>Eur. Rev. Med. Pharmacol. Sci.</i> 9:373-378, 2005.
/B.P./	Moreland et al., "Etanercept Therapy in Rheumatoid Arthritis," <i>Ann. Intern. Med.</i> 130:478-486, 1999.
/B.P./	Mpofu et al., "Anti-TNF- $\alpha$ Therapies: They Are All the Same (Aren't They?)," <i>Rheumatology</i> 44:271-272, 2005.
/B.P./	Murch et al., "Location of Tumour Necrosis Factor $\alpha$ by Immunohistochemistry in Chronic Inflammatory Bowel Disease," <i>Gut</i> 34:1705-1709, 1993.
/B.P./	Nanda et al., "Etanercept: a Clinical Review of Current and Emerging Indications," <i>Expert. Opin. Pharmacother.</i> 5:1175-1186, 2004.
/B.P./	Nikolaus et al., "Mechanisms in Failure of Infliximab for Crohn's Disease," <i>Lancet</i> 356:1475-1479, 2000.
/B.P./	Raza, "Anti-TNF Therapies in Rheumatoid Arthritis, Crohn's Disease, Sepsis, and Myelodysplastic Syndromes," <i>Microsc. Res. Tech.</i> 50:229-235, 2000.
/B.P./	Sandborn et al., "Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial," <i>Gastroenterology</i> 121:1088-1094, 2001.
/B.P./	Sands, "Biological Therapies for Ulcerative Colitis," <i>Acta Gastro-Enterologica Belgica</i> 64:205-209, 2001.
/B.P./	Schreiber et al., "Tumour Necrosis Factor $\alpha$ and Interleukin 1 $\beta$ in Relapse of Crohn's Disease," <i>Lancet</i> 353:459-461, 1999.
/B.P./	Selma et al., "Identification of Lymphotoxin and Tumor Necrosis Factor in Multiple Sclerosis Lesions," <i>J. Clin. Invest.</i> 87:949-954, 1991.
/B.P./	Sharief et al., "Association Between Tumor Necrosis Factor- $\alpha$ and Disease Progression in Patients with Multiple Sclerosis," <i>N. Eng. J. Med.</i> 325:467-472, 1991.
/B.P./	Shen et al., "Current Therapeutic Recommendations, <i>Infliximab for Ulcerative Colitis</i> ," <i>J. Clin. Gastroenterol.</i> 38:741-745, 2004.
/B.P./	Shou et al., "Identification of Blood Biomarkers of Rheumatoid Arthritis by Transcript Profiling of Peripheral Blood Mononuclear Cells From the Rat Collagen-Induced Arthritis Model," <i>Arthritis Res. Ther.</i> 8:R28, 2006.
/B.P./	Sieper et al., "New Treatment Options in Ankylosing Spondylitis: a Role for Anti-TNF $\alpha$ Therapy," <i>Ann. Rheum. Dis.</i> 60:iii58-iii61, 2001.
/B.P./	Song et al., "Serotonin Reuptake Inhibitors Reverse the Impairments in Behavior, Neurotransmitter and Immune Functions in the Olfactory Bulbectomized Rat," <i>Human Psychopharmacol.</i> 9:135-146, 1994.

EXAMINER	/Benjamin Packard/	DATE CONSIDERED	12/31/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50164/026005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/777,517
		Applicant Jost-Price et al.
		Filing Date February 12, 2004
		Group 1612
(37 C.F.R. § 1.98(b))		IDS Filed September 22, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/B.P./	Vladic et al., "Cerebrospinal Fluid and Serum Protein Levels of Tumour Necrosis Factor-Alpha (TNF- $\alpha$ ), Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R gp80) in Multiple Sclerosis Patients," <i>Cytokine</i> 20:86-89, 2002.

EXAMINER /Benjamin Packard/	DATE CONSIDERED 12/31/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	